SBP-0636457 (Synonyms: SBI-0636457; SB1-0636457) |
| Katalog-Nr.GC63870 |
SBP-0636457 (SB1-0636457) ist ein SMAC-Mimetikum und als IAP-Antagonist. SBP-0636457 bindet an die BIR-DomÄnen der IAP-Proteine mit einem Ki von 0,27 μM. SBP-0636457 kann fÜr die Erforschung von soliden Tumoren und hÄmatologischen Krebsarten verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1422180-49-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers[1][2].
SBP-0636457 (1-20 μM) demonstrates no cytotoxicity in BT474, BT549, MCF7, and MDA-MB-231 breast cancer cell lines up to a concentration of 20μM[1].SBP-0636457 (10-1000 nM; 20 h) is ef?cacious as TRAIL-sensitizing agents in MDA-MB-231 cells, with an EC50 of 9 nM[1].
[1]. Finlay D, et, al. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther. 2014 Jan; 13(1): 5-15.
[2]. Finlay D, et, al. Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. F1000Res. 2017 Apr 27; 6:587.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *